Evaluation of hematopoietic- and neurologic-expressed sequence 1-like (HN1L) protein levels in tissue and plasma of breast cancer patients

Abstract

Objectives: Breast cancer is the second leading cause of cancer deaths among women. Therefore, there is a need for new approaches that increase the success of treatment in breast cancer. Cancer stem cells (CSCs) are associated with treatment resistance and metastasis, which are important problems in cancer treatment including breast tumors. In this study, the Hematopoietic- and neurologic-expressed sequence 1-like (HN1L), also known as Jupiter microtubule associated homolog 2 (JPT2) protein levels which is involved in the self-renewal of CSCs were evaluated in common and rare breast tumor types.

Methods: In this context, HN1L protein levels were measured from plasma of 17 patients and from tumor and normal tissues of 9 patients by enzyme linked immunosorbent assay method.

Results: Mean HN1L levels were measured as 1.63 ± 0.88 ng/mL in plasma samples, 2.18 ± 0.75 ng/mL in tumor tissue samples and 2.71 ± 0.88 ng/mL in normal tissue samples. A significant difference was observed between mean HN1L levels in plasma and normal tissue (p < 0.05). Correlation of HN1L protein levels with clinicopathological characteristics were analyzed. Accordingly, HN1L levels were positively correlated with tumor size and invasion status (r=0.425; p < 0.05 and r=0.449; p < 0.05, respectively).

Conclusions: We believe that the importance of HN1L in management of breast cancers will be demonstrated more thoroughly when further studies are conducted with increased number of patients.

Keywords

• HN1L
• JPT2
• breast cancer
• cancer stem cell

References

1. 1. Ames BN, Gold LS, Willett WC. The causes and prevention of cancer. Proc Natl Acad Sci U S A 1995;92:5258-65.
2. 2. Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol 2022;95:20211033.
3. 3. Zhou G, Wang J, Zhang Y. Zhong C, Ni J, Wang L, et al. Cloning, expression and subcellular localization of HN1 and HN1L genes, as well as characterization of their orthologs, defining an evolutionarily conserved gene family. Gene 2004;331:115-23.
4. 4. Liu Y, Choi DS, Sheng J, Ensor JE, Liang DH, Rodriguez-Aguayo C, et al. HN1L promotes triple-negative breast cancer stem cells through LEPR-STAT3 pathway. Stem Cell Rep 2018;10: 212-27.
5. 5. Liu ZB, Ezzedine NE, Eterovic AK, Ensor JE, Huang HJ, Albanell J, et al. Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases. Breast Cancer Res Treat 2019;178:251-61.
6. 6. Jiao D, Zhang J, Chen P, Guo X, Qiao J, Zhu J, et al. HN1L promotes migration and invasion of breast cancer by up-regulating the expression of HMGB1. J Cell Mol Med 2021;25:397-410.
7. 7. Smith PE, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano M, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985;150:76-85.
8. 8. Kakarala M, Wicha MS. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 2008;26:2813-20.

9. 9. Bai X, Ni J, Beretov J, Graham P, Li Y. Cancer stem cell in breast cancer therapeutic resistance. Cancer Treat Rev 2018;69:152-63.
10. 10. İlvan Ş. Meme Karsinomu Patolojisi. İÜ Cerrahpaşa Tıp Fakültesi Sürekli Tıp Eğitimi Etkinlikleri 2006;54:65-71.
11. 11. Yousef AJA. Male breast cancer: epidemiology and risk factors. Semin Oncol 2017;44:267-72.
12. 12. Markou A, Tzanikou E, Lianidou E. The potential of liquid biopsy in the management of cancer patients. Semin Cancer Biol 2022;84:69-79.
13. 13. Thomas ML, Marcato P. Epigenetic modifications as biomarkers of tumor development, therapy response, and recurrence across the Cancer Care Continuum. Cancers (Basel) 2018;10:101.
14. 14. Asante DB, Calapre L, Ziman M, Meniawy TM, Gray ES. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: ready for prime time? Cancer Lett 2020;468:59-71.
15. 15. Cescon DW, Bratman SV, Chan SM, Siu LL. Circulating tumor DNA and liquid biopsy in oncology. Nat Cancer 2020;1:276-90.
16. 16. Veyssière H, Bidet Y, Penault-Llorca F, Radosevic-Robin N, Durando X. Circulating proteins as predictive and prognostic biomarkers in breast cancer. Clin Proteomics 2022;19:25.
17. 17. Aravanis AM, Lee M, Klausner RD. Next-generation sequencing of circulating tumor DNA for early cancer detection. Cell 2017;168:571-4.
18. 18. Campos-Carrillo A, Weitzel JN, Sahoo P, Rockne R, Mokhnatkin JV, Murtaza M, et al. Circulating tumor DNA as an early cancer detection tool. Pharmacol Ther 2020;207:107458.
19. 19. Mirzaei A, Madjd Z, Kadijani AA, Tavakoli-Yaraki M, Modarresi MH, Verdi J, et al. Evaluation of circulating cellular DCLK1 protein, as the most promising colorectal cancer stem cell marker, using immunoassay based methods. Cancer Biomark 2016;17:301-11.
20. 20. Christman EM, Chandrakesan P, Weygant N, Maple JT, Tierney WM, Vega KJ, et al. Elevated doublecortin-like kinase 1 serum levels revert to baseline after therapy in early stage esophageal adenocarcinoma. Biomark Res 2019;7:5.
21. 21. Nong S, Wang Z, Wei Z, Ma L, Guan Y, Ni J. HN1L promotes stem cell-like properties by regulating TGF-β signaling pathway through targeting FOXP2 in prostate cancer. Cell Biol Int 2022;46:83-95.
22. 22. Li L, Zheng YL, Jiang C, Fang S, Zeng TT, Zhu YH, et al. HN1L-mediated transcriptional axis AP-2γ/METTL13/TCF3-ZEB1 drives tumor growth and metastasis in hepatocellular carcinoma. Cell Death Differ 2019;26:2268-83.
23. 23. Wang ZY, Xiao W, Jiang YZ, Dong W, Zhang XW, Zhang L. HN1L promotes invasion and metastasis of the esophagogastric junction adenocarcinoma, Thorac Cancer 2021;12:650-8.
24. 24. Ertürk E, Sarımahmut M, Gökgöz MŞ. [Evaluation of the effectiveness of HN1L as a novel biomarker candidate in aggressive breast tumors]. Proceedings of the 7th International Medicine and Health Sciences Researches Congress (UTSAK) 2021;216-7. [Oral Presentation in Turkish]
25. 25. Sarımahmut M, Ertürk E, Gökgöz MŞ. Determination of the Potential of HN1L as a Biomarker in Luminal Type Breast Cancers. Proceedings of the VII. International Hippocrates Congress On Medical and Health Sciences 2021;16. [Oral Presentation in Turkish]